WORK Medical Subsidiary, Neologics Bioscience, Enters Into Key Service Agreement With GemPharmatech

WORK Medical Technology Group LTD (NASDAQ:WOK) ("WORK Medical" or the "Company"), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today is pleased to announce that its subsidiary, Neologics Bioscience Inc. ("Neologics"), has entered into a key service agreement (the "Agreement") with GemPharmatech Corporation ("GemPharmatech"), a Delaware-based leading contract research organization. ​This move is not only a significant milestone in WORK Medical's global expansion strategy and business diversification initiatives, but also signals a pivotal shift in the company's strategy—moving efficiently from capital injection to research and development (R&D) execution.

Pursuant to the Agreement, Neologics agrees to serve as an independent contractor to provide specified testing services for GemPharmatech. These services will cover the entire process from material preparation, serum titer analysis, hybridoma fusion and screening, antibody sequencing and production, to in vitro validation for several purified recombinant antibodies, as requested by GemPharmatech during the term of the Agreement. As consideration, GemPharmatech has agreed to pay US$114,000 in total to Neologisc for the services rendered under the work orders associated with the Agreement.